Ann: AusCann Receives Positive MOC from the U.S. FDA for CPAT-01, page-39

Very rough analysis, but if we had around 4 million out the door last financial year. Then we have coming in 500,000 rental income, approximating 1,500,000 tax credit!? And a bit of a caveat around the disputed amounts around the Chilean venture ($800,000 would need to double check that amount), would leave us between $1.2 - 2 million short.

Roughly $10 million cash on hand, is it true that we will be running out of money in mid 2023? Dermacann sales could change this picture to a break even type scenario. There is also potential for more merger or acquisition activity to take place.

Any thoughts on this? I haven't spent a lot of time crunching the numbers.